The cost of Zepbound (tirzepatide) is a key consideration for individuals seeking the medication. As a novel treatment, its pricing reflects research and development expenses, manufacturing, and market factors.
What is the list price for Zepbound?
The list price for Zepbound is $999.49 for a 28-day supply of any of its four dosage strengths [1]. This price point is before any potential discounts, coupons, or insurance coverage.
How can patients reduce the out-of-pocket cost of Zepbound?
Eli Lilly and Company, the manufacturer of Zepbound, offers a savings card program. Eligible commercially insured patients can save as little as $550 on their monthly prescription [2]. For patients without insurance or those who don't qualify for the savings card, Lilly offers a LillyDirect Direct Savings Card that can reduce the cost to as low as $550 per month for up to 12 months [3]. Eligibility criteria apply to these programs.
What is the difference between Zepbound and Mounjaro?
Zepbound and Mounjaro share the same active ingredient, tirzepatide [1]. However, Zepbound is specifically indicated for chronic weight management in adults with obesity or overweight and at least one weight-related condition [1]. Mounjaro is approved for the treatment of type 2 diabetes [4]. While both can lead to weight loss, their primary regulatory approvals differ.
When will Zepbound's patent protection end?
Patent protection for Zepbound is a critical factor in its long-term availability and potential for generic competition. Information regarding specific patent expiry dates for tirzepatide can be found through resources like DrugPatentWatch.com [5]. These patents are crucial for determining when biosimilar or generic versions might enter the market, potentially influencing future costs.
Are there other weight loss medications available besides Zepbound?
Yes, several other medications are available for chronic weight management. These include GLP-1 receptor agonists like semaglutide (Wegovy) and liraglutide (Saxenda), as well as other classes of drugs. The choice of medication often depends on individual health factors, treatment goals, and physician recommendations.
What are the clinical trial results for Zepbound regarding weight loss?
Clinical trials for Zepbound have demonstrated significant weight loss. In the SURMOUNT-1 trial, participants treated with Zepbound achieved an average weight reduction of up to 22.5% over 72 weeks compared to placebo [6]. These results underscore the efficacy of the drug in weight management.
---
Sources:
[1] https://www.zepbound.com/
[2] https://www.zepbound.com/savings-and-support
[3] https://www.lillydirect.com/savings-cards/zepbound-savings-card
[4] https://www.mounjaro.com/
[5] https://drugpatentwatch.com/
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa2302097